Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from InnoCare Pharma Ltd. ( (HK:9969) ).
InnoCare Pharma Limited has received approval from the National Medical Products Administration for zurletrectinib, a second-generation pan-TRK inhibitor, for treating adult and adolescent patients with solid tumors harboring NTRK gene fusions in China. The drug demonstrated high efficacy and a favorable safety profile in clinical trials, offering a significant advancement over first-generation TRK inhibitors. This approval positions InnoCare as a key player in addressing unmet clinical needs in the oncology sector, particularly for tumors with NTRK gene fusions, which are present in over 26 types of tumors and affect approximately 6,500 new patients annually in China.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$19.60 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative treatments for various medical conditions. The company is engaged in the research and development of small molecule drugs, particularly targeting cancer therapies, and operates primarily in the Chinese market.
Average Trading Volume: 11,594,070
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.48B
Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.